Stock NAMS FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

End-of-day quote Nasdaq
Other stock markets
 18:00:00 2024-05-27 EDT 		5-day change 1st Jan Change
19.41 EUR +3.13% Intraday chart for Frazier Lifesciences Acquisition Corporation +1.62% +73.77%
05-21 NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings CI
05-16 Transcript : NewAmsterdam Pharma Company N.V. - Special Call

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings
CI
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M
MT
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
CI
Newamsterdam Pharma Company N.V. Doses First Patient in Phase 3 Tandem Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with Hefh And/Or Ascvd
CI
NewAmsterdam Pharma Full Year 2023 Net Loss Widens, Revenue Drops
MT
Newamsterdam Pharma Company N.V. Announces Initial Data from Phase 2A Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an Apoe4 Mutation
CI
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
NewAmsterdam Pharma Company N.V. Provides Clinical Development Updates
CI
Newamsterdam Pharma Company N.V. Completes Enrollment in Pivotal Phase 3 Broadway Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia And/Or Established Atherosclerotic Cardiovascular Disease
CI
NewAmsterdam Pharma Company N.V. Announces Positive Topline Results from Phase 2B Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
CI
NewAmsterdam Pharma Company N.V. Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
CI
NewAmsterdam Pharma Company N.V. Provides Clinical Development Updates
CI
NewAmsterdam Pharma Completes Enrollment in Phase 3 Trial of Obicetrapib to Treat Heterozygous Familial Hypercholesterolemia
MT
Newamsterdam Pharma Completes Enrollment in Pivotal Phase 3 Brooklyn Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
CI
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
GL
NewAmsterdam Pharma Company N.V. Appoints John W. Smither as Independent Director
CI
Newamsterdam Pharma Company N.V. Announces Positive Results from Rose2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
CI
VectivBio Announces Results of Extraordinary General Meeting-Wouter Joustra Elected to the Board of Directors
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. News Frazier Lifesciences Acquisition Corporation
  5. Highlights